T2-weighted magnetic resonance imaging of the liver: evaluation of the effect in signal intensity after Gd-EOB-DTPA enhancement. J Comput Assist Tomogr. 2010;34:182-186. [PMID: 20351500 DOI: 10.1097/rct.0b013e3181bc961b]

LI-RADS v2018 category and imaging features: inter-modality agreement between contrast-enhanced CT, gadoxetate disodium-enhanced MRI, and extracellular contrast-enhanced MRI

PURPOSE

To perform an intra-individual comparison of LI-RADS category and imaging features in patients at high risk of hepatocellular carcinoma (HCC) on contrast-enhanced CT, gadoxetate disodium-enhanced MRI (EOB-MRI), and extracellular agent-enhanced MRI (ECA-MRI) and to analyze the diagnostic performance of each imaging modality.

METHOD

This retrospective study included cirrhotic patients with at least one LR-3, LR-4, LR-5, LR-M or LR-TIV observation imaged with at least two imaging modalities among CT, EOB-MRI, or ECA-MRI. Two radiologists evaluated the observations using the LI-RADS v2018 diagnostic algorithm. Reference standard included pathologic confirmation and imaging criteria according to LI-RADS v2018. Imaging features were compared between different exams using the McNemar test. Inter-modality agreement was calculated by using the weighted Cohen's kappa (k) test.

RESULTS

A total of 144 observations (mean size 34.0 ± 32.4 mm) in 96 patients were included. There were no significant differences in the detection of major and ancillary imaging features between the three imaging modalities. When considering all the observations, inter-modality agreement for category assignment was substantial between CT and EOB-MRI (k 0.60; 95%CI 0.44, 0.75), moderate between CT and ECA-MRI (k 0.46; 95%CI 0.22, 0.69) and substantial between EOB-MRI and ECA-MRI (k 0.72; 95%CI 0.59, 0.85). In observations smaller than 20 mm, inter-modality agreement was fair between CT and EOB-MRI (k 0.26; 95%CI 0.05, 0.47), moderate between CT and ECA-MRI (k 0.42; 95%CI -0.02, 0.88), and substantial between EOB-MRI and ECA-MRI (k 0.65; 95%CI 0.47, 0.82). ECA-MRI demonstrated the highest sensitivity (70%) and specificity (100%) when considering LR-5 as predictor of HCC.

CONCLUSIONS

Inter-modality agreement between CT, ECA-MRI, and EOB-MRI decreases in observations smaller than 20 mm. ECA-MRI has the provided higher sensitivity for the diagnosis of HCC.

Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up

OBJECTIVE

The aim of this study was to retrospectively analyze the outcome of LR-3 and LR-4 without arterial phase hyperenhancement (APHE), and identify which features could predict LR-5 progression on serial Gd-EOB-DTPA-enhanced MRI follow-up.

METHODS

Forty-nine cirrhotic patients with 55 LR-3 and 19 LR-4 without APHE were evaluated. Observations were classified as decreased, stable or increased in category at follow-up. Observation size and LI-RADS major and ancillary features were evaluated.

RESULTS

Seventeen/fifty-five (31%) LR-3 and 8/19 (42%) LR-4 progressed to LR-5 at follow-up. Baseline LI-RADS major and ancillary features were not significantly different among LR-3 and LR-4. A diameter ≥ 10 mm significantly increased LR-5 progression risk of LR-3 (OR = 6.07; 95% CI: 0.12; 60.28]; P < .001). LR-4 with a diameter ≥ 10 mm more likely become LR-5 at follow-up (OR = 8.95; 95% CI: 0.73; 111.8; P = .083]).

CONCLUSION

LR-3 and LR-4 without APHE were often downgraded or remained stable in category on Gd-EOB-DTPA-enhanced MRI follow-up.

Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients

PURPOSE

To retrospectively analyze the evolution of indeterminate hepatocellular nodules in cirrhotic patients on serial Gd-EOB-DPTA-enhanced MRI, and to identify predictors of HCC development.

MATERIALS AND METHODS

This IRB approved study included 33 cirrhotic patients with 69 indeterminate hepatocellular nodules (mean diameter 1.1 cm) at baseline Gd-EOB-DPTA-enhanced MRI and a Gd-EOB-DPTA-enhanced-MRI follow-up of at least 2 years. Two radiologists evaluated size and signal intensity of each nodule at baseline and follow-up. Age, cirrhosis etiology, and HCC history were recorded. Data were compared between nodules that became HCCs at follow-up (HCC) and those that did not (no-HCC).

RESULTS

On follow-up, 5/69 nodules became HCCs and 64/69 showed indeterminate characteristics. HCC history was more frequently found in HCCs than in no-HCCs. Age, sex, and cirrhosis etiology were not significantly different between HCCs and no-HCCs. HCCs had a significantly greater baseline diameter and increase in size than no-HCCs. Hepatobiliary phase hypointensity was significantly more common in HCCs than in no-HCCs. Multivariate regression analysis showed that increase in size (OR 10.48; sensitivity, 100%; specificity, 81.2%; p < 0.001) and hepatobiliary phase hypointensity (OR 1.02; sensitivity, 100%; specificity, 78.1%; p < 0.001) was associated with HCC development.

CONCLUSION

Indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients rarely became HCCs. Hepatobiliary phase hypointensity had a weak association with HCC development.

Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acid

Gadoxetic acid improves detection and characterization of focal liver lesions in cirrhotic patients and can estimate liver function in patients undergoing liver resection. The purpose of this article is to describe the optimal gadoxetic acid study protocol for the liver, the unique characteristics of gadoxetic acid, the differences between gadoxetic acid and extra-cellular gadolium chelates, and the differences in phases of enhancement between cirrhotic and normal liver using gadoxetic acid. We also discuss how to obtain and recognize an adequate hepatobiliary phase.

MR liver imaging with Gd-EOB-DTPA: The need for different delay times of the hepatobiliary phase in patients with different liver function

PURPOSE

To determine the optimal hepatobiliary delay time after Gd-EOB-DTPA injection for lesion characterization in cirrhosis patients with different liver function.

MATERIALS AND METHODS

Ninety consecutive patients with liver cirrhosis who underwent Gd-EOB-DTPA-enhanced MRI for the evaluation of known or suspected focal liver lesions were enrolled in this retrospective study. The patients were divided into Child-Pugh A, B and C groups depending on their liver function through the Child-Pugh classification. Hepatobiliary phase images obtained at 5, 10, 15, and 20min were assessed in each group by the following items: parenchymal enhancement, contrast agent excretion into the bile ducts and ureter, and contrast- and signal-to-noise ratios for lesions.

RESULTS

In the Child-Pugh A group, parenchymal enhancement increased significantly from 5min to 15min (P<0.05), and stabilized at 20min (P=0.22). However, there was no significant difference in parenchymal enhancement among all of the hepatobiliary phases in the Child-Pugh B and C groups. The biliary contrast agent excretion was first observed before 20min in all of the patients in the Child-Pugh A group, at 20min in 4 patients (25%) in the Child-Pugh B group, and after 20min in 11 patients (78.6%) in the Child-Pugh C group. The numbers of patients whose urethral contrast agent excretion was first observed at 5min in the Child-Pugh A, B and C groups were 38 (63.3%), 12 (75.0%) and 11 (78.6%), respectively. The CNR of the lesions increased significantly (P<0.05), up to 15min after enhancement without a further increase at 20min in the Child-Pugh A group; however, no significant change was found from 5min to 20min in the Child-Pugh B and C groups. For the SNR of lesions, there was no significant difference at 5, 10, 15 and 20min in all of the groups.

CONCLUSIONS

A delay time of 15min for the hepatobiliary phase was sufficient for patients with mild liver dysfunction who were classified as Child-Pugh A. Nevertheless, for the patients with moderate or severe liver dysfunction who were classified as Child-Pugh B or C, a delay time longer than 5min is meaningless for lesion characterization.

Diffusion- and T₂-weighted MR imaging of the liver: effect of intravenous administration of gadoxetic acid disodium

PURPOSE

We evaluated the effect of intravenous administration of gadoxetic acid disodium to hepatic lesions and liver parenchyma on T₂-weighted (T₂WI) and diffusion-weighted imaging (DWI).

MATERIALS AND METHODS

One hundred and one consecutive patients with 259 hepatic lesions underwent T₂WI and DWI (b-values of 500 and 1000 s/mm²) before and after gadoxetic acid administration. We compared the ratio of signal intensity (SIR) of the liver parenchyma and hepatic lesions, the ratio of contrast intensity of the lesion to the liver (CIR), the apparent diffusion coefficients (ADCs) of the liver and lesions, and lesion detectability between pre- and post-contrast images.

RESULTS

SIRs, CIRs, and ADC of focal hepatic lesions were comparable on pre- and post-contrast images, and lesion detectability did not differ significantly between pre- and post-contrast T₂WI and DWI. The SIRs of the liver parenchyma were significantly lower on post-contrast DWI (1.4±0.68 [b=500 s/mm²] and 1.71±0.67 [b=1000 s/mm²]) than pre-contrast images (1.89±0.68 [b=500 s/mm²] and 2.26±0.78 [b=1000 s/mm²]) (P<0.001). ADCs of the liver parenchyma were also significantly decreased on post-contrast DWI (0.77±0.32 mm²/s) than pre-contrast images (0.64±0.33 mm²/s) (P=0.001).

CONCLUSION

T₂WI and DWI after administration of gadoxetic acid are feasible and do not compromise the SIR, CIR, and ADC of focal hepatic lesions. However, the signal intensity of DWI and ADC value of the liver parenchyma were decreased on gadoxetic acid-enhanced hepatocyte phase images.

Effects of gadoxetic acid on quantitative diffusion-weighted imaging of the liver

PURPOSE

To prospectively evaluate the effect of gadoxetic acid (Gd-EOB-DTPA; Primovist, Bayer-Schering, Berlin, Germany) on quantitative diffusion-weighted imaging (DWI) using the Le Bihan IntraVoxel Incoherent Motion model and considering separately the following parameters: slow diffusion coefficient (D), fast diffusion coefficient (D*), perfusion fraction (PF), and apparent diffusion coefficient (ADC).

MATERIALS AND METHODS

Twenty-four consecutive patients were submitted to the same magnetic resonance (MR)-DWI acquisition before and after gadoxetic acid administration. Patients were divided into four groups according to the time at which the DW sequence was repeated, then 5, 10, 15, 20 minutes after contrast agent administration. A total of 48 manually drawn regions of interest (ROIs) of about 1200 pixels were placed in the middle right liver lobe. The mean and standard deviation (SD) were calculated in each group/patient for every DWI-related parameter. Analysis of variance was performed (threshold P = 0.05). Bonferroni and Games-Howell post-hoc tests were applied if significant differences were found among groups; otherwise, data were averaged together.

RESULTS

D, D*, PF, and ADC did not show any significant difference before and after contrast agent administration, at any time.

CONCLUSION

It is possible to perform DW acquisitions after gadoxetic acid administration without any significant variation of the values of DW-related parameters under consideration in this study.

Effects of gadoxetic acid on liver elasticity measurement by using magnetic resonance elastography

The purpose of this study was to evaluate the effect of gadoxetic acid (Gd-EOB-DTPA) on measurements of liver stiffness by using magnetic resonance elastography (MRE). In this study, 104 consecutive patients (mean age, 67.7±9.4 years) underwent MRE using a 1.5-T MR scanner equipped with a cylindrical passive driver that was placed across the right chest wall for delivering vibrations. Axial gradient-echo images, which were automatically converted to elastograms that represented stiffness (kPa), were acquired using a continuous sinusoidal vibration of 60 Hz. Two raters independently placed a region of interest on the right lobe of the liver on the elastograms obtained before and after Gd-EOB-DTPA was administered. Liver stiffness was measured using these two elastograms and compared using a paired t test and correlation analysis. No significant difference was observed in liver stiffness before and after Gd-EOB-DTPA was administered (Rater 1, P=.1200; Rater 2, P=.3585). The correlation coefficients were 0.986 (Rater 1) and 0.984 (Rater 2), indicating excellent correlation between the stiffness values before and after Gd-EOB-DTPA was administered. Liver stiffness measured by MRE did not differ before and after Gd-EOB-DTPA was administered.

[An experimental study of the optimal flip angle for hepatocellular magnetic resonance imaging with Gd-EOB-DTPA]

Gadoxetate Sodium (Gd-EOB-DTPA) is a relatively new contrast agent used for liver examination by magnetic resonance (MR) imaging. The setting of the flip angle (FA) is very important to obtain images with high contrast in hepatocellular MR imaging. The aim of this study was to determine the optimal FA for hepatocellular MR imaging. Optimal FA was estimated using a visual evaluation by observers. We made the visual evaluation with a paired comparison test. When the overall characteristic showed a significant difference, we then evaluated the optimal FA using a yardstick analysis. The visual evaluation by observers indicated that the FA was best at 22 degrees for the overall characteristic, the contrast characteristic, and the sharpness characteristic, and for the noise characteristic, the best FA was 18 degrees. All characteristics showed a significant difference between 18 and 22 degrees. Based on our results, the most important factor was the contrast characteristic for the visual evaluation, and we concluded that the optimal FA in hepatocelluar MR imaging was 22 degrees.